Del.icio.us
Google
Yahoo MyWeb
Facebook
Biodel Overview
Biodel has developed several therapeutic candidates for the treatment of diabetes and osteoporosis. All of Biodel's products were discovered in-house using Biodel's proprietary VIAdel™ technology, which reformulates existing, FDA approved peptide drugs. Biodel's lead product is VIAject™. VIAject™ is a rapid-acting injectable meal-time insulin. Based on our clinical trial data to date, we believe...More»
Biodel has developed several therapeutic candidates for the treatment of diabetes and osteoporosis. All of Biodel's products were discovered in-house using Biodel's proprietary VIAdel™ technology, which reformulates existing, FDA approved peptide drugs. Biodel's lead product is VIAject™. VIAject™ is a rapid-acting injectable meal-time insulin. Based on our clinical trial data to date, we believe that VIAject™ delivers insulin into the bloodstream faster than currently approved meal-time insulins including the rapid acting insulin analog Humalog®, which is the market leader. VIAject™ is currently being tested in two Phase III clinical trials, which are expected to be completed by the end of 2007. Biodel is also conducting a Phase I clinical trial evaluating VIAtab™, an oral (sublingual) tablet formulation of insulin.«Less
Key People
Management
Board of Directors
Advisors
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 08/01/2006 | Series B | 21M | Unknown |
Products
| Name: | VIAject |
| Product URL: | http://www.biodel.com/pipeline/viaject.htm |
| Description: | Our lead clinical candidate is VIAject™, a very rapid-acting form of injectable human insulin for meal-time use by patients with Type 1 or Type 2 diabetes. VIAject™ is comprised of commercially available recombinant human insulin and our proprietary formulation of ingredients, all of which are Generally Regarded As Safe (GRAS) by the FDA. Our proprietary formulation delivers insulin in a form which more closely resembles the way a normal body uses insulin to help glucose enter the body's cells, providing energy that allows the body to function. Currently, insulin therapies are not delivered quickly enough to simulate the desired meal-time insulin spike. In tests to date, the VIAject™ formulation of insulin promotes a more rapid absorption, which more closely mirrors the effects of naturally produced insulin in non-diabetics thereby providing more effective blood glucose control. This novel therapy is currently undergoing two pivotal Phase III clinical studies. The two studies, one involving 400 patients with Type 1 diabetes and the other involving 400 patients with Type 2 diabetes, are comparing the effects of VIAject™ to Humulin®, the leading recombinant human insulin. |
| Screenshots: |
|
Competitors
Profile
OpinionsRelated Companies
No related companies were found.
User Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Similar Companies
View All Similar »Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | n/a | ||
Biodel on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.
Related Jobs
loading...